[{"uuid": "0281fabd-4295-38a9-8907-1f007e2f029d", "title": "All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/know-gain-therapeutics-ganx-rating-170010869.html", "providerPublishTime": 1737046810, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/KwglccBRAqiWaro_ZvjSew--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GANX"]}, {"uuid": "a60333c5-cd20-3d95-99f1-de14f44e62e9", "title": "Best Momentum Stocks to Buy for January 9th", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/best-momentum-stocks-buy-january-151500839.html", "providerPublishTime": 1736435700, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/d3TGN2WJK1W6Cd3Y8QmP0w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FHB", "TRV"]}, {"uuid": "4fbe950f-fea7-3c59-ad0a-962f11b30671", "title": "Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/gain-therapeutics-announces-formation-clinical-130000745.html", "providerPublishTime": 1736341200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/oFx8unEnSuXIwEM9d5jRvg--~B/aD03Mjt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 150, "height": 72, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zmH_JzWjbp5As8YESjRkuQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GANX"]}, {"uuid": "ca300cce-4c4b-3486-8038-bdd60e1a65ea", "title": "Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/gain-therapeutics-appoints-gene-mack-120000865.html", "providerPublishTime": 1736251200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/oFx8unEnSuXIwEM9d5jRvg--~B/aD03Mjt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 150, "height": 72, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zmH_JzWjbp5As8YESjRkuQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GANX"]}, {"uuid": "b8ae0acf-779b-38bd-80f7-d12d150bd4c8", "title": "Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/gain-therapeutics-says-australia-approves-140028394.html", "providerPublishTime": 1734962428, "type": "STORY", "relatedTickers": ["GANX"]}, {"uuid": "7a6a94d7-84b2-3e38-8ece-ac1333104b7e", "title": "Gain Therapeutics\u2019 GT-02287 study to deliver positive findings, says Roth MKM", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/gain-therapeutics-gt-02287-study-124007799.html", "providerPublishTime": 1735130407, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/c8pJ6Hc13EFaByQh6DEJ0A--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/bircVCqs.PWolEadE6JkKg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GANX"]}, {"uuid": "90afe675-4026-3ed8-b7c4-cb62233aebe7", "title": "Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson\u2019s Disease", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/gain-therapeutics-initiates-phase-1b-123000860.html", "providerPublishTime": 1734957000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/oFx8unEnSuXIwEM9d5jRvg--~B/aD03Mjt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 150, "height": 72, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zmH_JzWjbp5As8YESjRkuQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GANX"]}, {"uuid": "c3b4e725-cc44-3a1c-b473-24026c648264", "title": "Roth Initiates Gain Therapeutics at Buy With $7 Price Target", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/roth-initiates-gain-therapeutics-buy-131132110.html", "providerPublishTime": 1733490692, "type": "STORY", "relatedTickers": ["GANX"]}, {"uuid": "794d013f-1fc5-3bb3-8549-3a256725d1b4", "title": "Gain Therapeutics To Present At Biotech Showcase 2025", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/gain-therapeutics-present-biotech-showcase-133000049.html", "providerPublishTime": 1733923800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/oFx8unEnSuXIwEM9d5jRvg--~B/aD03Mjt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 150, "height": 72, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zmH_JzWjbp5As8YESjRkuQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GANX"]}, {"uuid": "9b27867e-fa29-3572-a795-74f6e8fe3331", "title": "Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/gain-therapeutics-reports-financial-results-210500770.html", "providerPublishTime": 1731618300, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/oFx8unEnSuXIwEM9d5jRvg--~B/aD03Mjt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 150, "height": 72, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zmH_JzWjbp5As8YESjRkuQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d5ec18bc73eadac82334f344250a9a02", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GANX"]}]